Jun 21 |
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
|
Jun 20 |
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
|
Jun 18 |
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
|
Jun 5 |
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
May 29 |
Altimmune: Going All-In On Pemvidutide
|
May 29 |
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
|
May 28 |
Altimmune: A Potential Minor Player In The Massive GLP-1 Space
|
May 28 |
Altimmune's Pemvidutide Is Not To Be Dismissed
|
May 27 |
Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
|
May 21 |
Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
|